RISKS OF VISANNETTE (DIENOGEST) AND JASMIN (DROSPIRENONA). THE MINISTRY OF HEALTH HAS BEEN INFORMED OF THESE HEALTH HAZARDS
THEY ARE NOT CUTS … THE MINISTRY OF HEALTH SUPPORTS PHARMACEUTICALS, OVERCOME THE REALITY OF THESE RISKS AND SUPPRESS THE CONTRACEPTIVES OF THE THIRD AND FOURTH GENERATION OF THEIR FINANCING !!! THIS NOTICE IS JANUARY 2013
THIS JULY 2013 … AS WE CAN VERIFY, THE MINISTRY OF HEALTH IS REMARKED TO FINANCE DROSPIRENONE AND THE FOURTH GENERATION TREATMENTS, BUT IT DOES NOT GIVE EXPLANATIONS AND SAYS FOR ECONOMIC REASONS. LEAVING WOMEN TO MERCED FROM THE PHARMACEUTICAL INDUSTRY AND PROFESSIONALS WITHOUT SCRUPULS. THE VISANNETTE IS ALMOST 60 EUROS / MONTH.
http://sociedad.elpais.com/sociedad/2013/07/09/actualidad/1373402261_364374.HTML ADAEC ECHOES THE WITHDRAWAL AND DENOUNCES THE MINISTRY OF HEALTH FOR ITS SUPPORT TO THE PHARMACEUTICAL INDUSTRY AND NOT TO WOMEN. THE SAME REALITY THAT FRANCE HAS
THE DIFFERENT GENERATIONS OF THE CONTRACEPTIVE PILL. VISANETTE HAS FOUR TIMES MORE SIDE EFFECTS NOT THOSE OF THE FOURTH GENERATION …. IT HAS FOUR TIMES MORE SIDE EFFECTS AND THREAT OF RISKS. Fourth generation drospirenone and dienogest !!!!! ……
Have there been any other previous lawsuits against laboratories on this matter?
– Already in 2002 the European regulatory agencies expressed their caution regarding venous thrombosis produced by fourth generation contraceptives (Yasmin, chondrospirenone) following the death of a 17-year-old girl. In the United States, too, there have been numerous lawsuits against Bayer claiming that Yasmin and Yasminelle increase the risk of thrombosis, including arterial thrombosis, which leads to serious heart attacks and strokes.
Epidemiological studies have revealed an increased risk of stroke
In 2010 there were also massive lawsuits in Canada against Bayer for the risk of heart attacks and strokes associated with these same compounds. They have been set up as a mass legal action (class action) and the hearing of the Canadian process will start on January 28, 2013.
The Ministry of Health in Spain continues to support the Pharmaceuticals and from ADAEC denouncing it with information
ation and data.
DANGERS AND RISKS OF DROSPIRENONE AND DIENOGEST
CATALAN INSTITUTE OF PHARMACEUTICALS FOUNDATION
HIDDEN LUPRON CLINICAL TRIAL DATA
by adaec_admin | Jan 14, 2016 | 7.
May 2, 2014 – for ethics of impact – in Clinical Ethics, Health Research, Research Ethics – 4 Comments
For twenty-five years Lynne Millican has been promoting awareness of, and trying to advance research into, the serious problems associated with the Lupron drug.
In 1989, I received a prescription for the drug Lupron from a world-renowned Boston hospital for the treatment of endometriosis and infertility. Given the prestige of the institution, and the confidence I had in my doctor, when I was told that Lupron had been used safely around the world, I had no reason to doubt what I heard.
Shortly after I started taking the drug, I experienced worrisome symptoms, including hot flashes, insomnia, bone pain, gastrointestinal problems and headaches, among others. I began to question my treatment, and began scrubbing medical libraries and FDA documents to get information to explain the adverse effects I was experiencing.
After years of research, I had good reason to believe that Lupron’s use for endometriosis was based on fraudulent clinical trial data. In 1995, I identified “manipulated numbers” in a study conducted by a leading Lupron researcher, who was later found to have “fabricated and falsified data” in four other Lupron studies.
Over the past twenty-five years, I have written numerous letters to the FDA, testified before Congress, petitioned consumer protection groups, and harassed the media in a perpetual attempt to provoke awareness about, and research into, Lupron. While there has been some media attention about Lupron’s risks, no agency has acknowledged or addressed data from questionable clinical Lupron trials, iatrogenic injuries accumulate among those who have used Lupron, or the marginalization of Lupron victims. Emails to my website, Lupron Victims Hub, from victims who need help are deeply disturbing and heartbreaking; so many young and middle-aged lives (and families) devastated. Since 2009, thousands of people have been voicing serious and disabling complaints under conditions and/or after Lupron, and have similarly asked Congress for an investigation, without any results.
In going to court for justice and relief, the first Lupron victim/plaintiff to go to trial (Karin Klein v. TAP/Abbott, 2011) was met with a disconcerting array of perjury by medical experts on the defendants and the simultaneous silencing and preventing of medical expert from presenting facts. TAP/Abbott’s medical expert stated, under oath, that it was “biologically impossible for Lupron to affect the thyroid gland,” despite extensive published evidence to the contrary. After being given inaccurate information, the jury ruled against the disabled plaintiff, a seventeen-year-old boy who developed (among other problems) a thyroid disorder after Lupron. The plaintiff’s appeal to the Ninth Circuit and U.S. Supreme Court fell on deaf ears, no doubt deterring future Lupron litigation.
During the trial, Klein’s medical expert, world-renowned endometriosis surgeon Dr. David Redwine, had access to thousands of pages of TAP/Abbott’s raw data from the Lupron endometriosis clinical trials. Dr. Redwine found that “62.5% of patients had not recovered baseline estrogen levels within one year of leaving Lupron” identifying “definitive evidence of long-term damage to ovarian function. Despite this damaging data from clinical trials, the manufacturer of Lupron claims on its label that Lupron-induced estrogen depletion is “completely reversible when treatment is discontinued. The corresponding raw data is now under a federal court seal.
In October 2011 Dr. Redwine provided the FDA with a 300-page Lupron Review alerting them to hidden data and fraudulent results that were not disclosed to the FDA (or consumers) on (or since) the approval of Lupron 1990 for the treatment of pain in endometriosis. In 2013 the FDA response, which concluded that regulatory action was not necessary, failed to even mention the fraudulent data and results.
I have recently written several motions on behalf of another Lupron victim who is representing herself in court because her attorney withdrew and she has been unable to find adequate legal assistance. These motions ask the court to unseal the endometriosis clinical trial data (originally owned by TAP/Abbott and now owned by Abbvie). The judge has taken these motions under consideration. The explicit attempt by TAP/Abbott/Abbvie to keep their clinical trial data secret (and under court seal) suggests that the company has something to hide.
It is inconceivable and unacceptable, that any disabled Lupron victim like myself would have to spend twenty-five years to make the “guardians of public safety” – those of the FDA, legislators, Congress, the courts and consumer protection groups do their jobs. When the FDA refuses to investigate evidence of fraudulent data, when legislators and Congress fail to act, where does one go, and when the Supreme Court refuses to address perjury and denial of the right to a fair trial, what can be done?
There must be an army of legal and medical experts exploring and exposing the nightmare that is Lupron. When each new contact with me victimizes Lupron, what should I tell them?
Lynne Millican was a career admission unit, psychiatric nurse until physically disabled by Lupron. Currently, she serves as a resource for, and (as she can) advocates on behalf of, Lupron victims through her website.